Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 27Cisplatin 18Cetuximab 12Carboplatin 12Surveys and Questionnaires 8Radiotherapy 8Paclitaxel 8Docetaxel 6Radiotherapy, Intensity-Modulated 5Surgical Procedures, Operative 4dostarlimab 3Therapeutics 3Standard of Care 3Fluorouracil 3Cyclophosphamide 3Chemoradiotherapy 3Blood Specimen Collection 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3toripalimab 2nimotuzumab 2fludarabine 2durvalumab 2atezolizumab 2abemaciclib 2X-Rays 2Taxes 2Radiosurgery 2Radiation 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × RC48 antibody × 90 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡